Key publications
All Publications
- Rombach Saskia M., Aerts Johannes M. F. G., Poorthuis Ben J. H. M., Groener Johanna E. M., Donker-Koopman Wilma, Hendriks Erik, Mirzaian Mina, Kuiper Sijmen, Wijburg Frits A., Hollak Carla E. M., Linthorst Gabor E. Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome PLoS ONE 2012;7 (10):e47805-(7 p.) [PubMed]
- Eng C. M., Guffon N., Wilcox W. R., Germain D. P., Lee P., Waldek S., Caplan L., Linthorst G. E., Desnick R. J. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease New England journal of medicine 2001;345 (1):9-16 [PubMed]
- Wilcox William R., Banikazemi Maryam, Guffon Nathalie, Waldek Stephen, Lee Philip, Linthorst Gabor E., Desnick Robert J., Germain Dominique P. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease American journal of human genetics 2004;75 (1):65-74 [PubMed]
- Linthorst Gabor E., Hollak Carla E. M., Donker-Koopman Wilma E., Strijland Anneke, Aerts Johannes M. F. G. Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta Kidney international 2004;66 (4):1589-1595 [PubMed]
- Kemp Stephan, Huffnagel Irene C., Linthorst Gabor E., Wanders Ronald J., Engelen Marc Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history Nature reviews. Endocrinology 2016;12 (10):606-615 [PubMed]